Q32 Bio (QTTB) Amortizatization of Intangibles (2018 - 2026)
Q32 Bio (QTTB) recorded quarterly Amortizatization of Intangibles of $163000.0 in Q1 2026, down 73.79% quarter-over-quarter from $622000.0 in Q4 2025, and up 7.95% on a YoY basis from $151000.0 in Q1 2025.
Q32 Bio (QTTB) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Q32 Bio's Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $163000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 7.95% year-over-year to $163000.0; the TTM figure through Mar 2026 stood at $634000.0 (up 174.46% YoY), while the FY2025 annual figure was $622000.0, up 181.45% from the prior year.
- Amortizatization of Intangibles was $163000.0 for Q1 2026 at Q32 Bio, down from $622000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.1 million in Q4 2022 to a low of -$306000.0 in Q3 2025.
- Historically, Amortizatization of Intangibles has averaged $205705.9 across 5 years, with a median of $141000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles soared 450.0% in 2023, then sank 251.8% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.1 million in 2022, then tumbled by 87.07% to $139000.0 in 2023, then tumbled by 251.8% to -$211000.0 in 2024, then jumped by 394.79% to $622000.0 in 2025, then slumped by 73.79% to $163000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $163000.0 (Q1 2026), $622000.0 (Q4 2025), and -$306000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | 163,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 163,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 622,000.00 |
| Dec 31, 2025 | 622,000.00 |
| Sep 30, 2025 | -306,000.00 |
| Sep 30, 2025 | -306,000.00 |
| Jun 30, 2025 | 155,000.00 |
| Jun 30, 2025 | 155,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Dec 31, 2024 | -211,000.00 |
| Dec 31, 2024 | -211,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 65,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 139,000.00 |
| Dec 31, 2023 | 139,000.00 |